Burns
Volume 31, Issue 7 , Pages 866-869 , November 2005

Effect of systematic empiric treatment with imipenem on the bacterial ecology in a burns unit

,Accepted 13 April 2005.

References 

  1. Vindenes H, Bjerknes R. Microbial colonisation of large wounds. Burns. 1995;21:575–579
  2. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2003;31(Suppl 4):S131–S138
  3. Kollef MH. The importance of appropriate initial antimicrobial therapy for hospital – acquired infections. Am J med. 2003;115(7):582–584
  4. Carvallo JD, Fabre R, Jehl F, Rapp C, Garrabé E. β-Lactam antibiotics. EMC-Maladies infectieuses. 2004;1:129–202
  5. Jones R. Resistance patterns among nosocomial pathogens: trend over the past few years. Chest. 2001;119(2 Suppl):397S–404S
  6. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator associated pneumonia. Crit care med. 2004;32:2183–2190
  7. Boselli E, Allaouchiche B. Diffusion of anibiotics into lung tissue. Critical analysis of the literature. Ann Fr Anesth Réanim. 2001;20:612–630
  8. Maire P, Corvaisier S, Bouvier d’Yvoire M, et al. Pharmacocinétique/pharmacodynamie clinique des antibiotiques. In: Précis de bactériologie clinique, editor. ESKA. p. 720.
  9. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis. 1998;27:10–22
  10. Stein GE. Phamacokinetics and phamacodynamics of fluoroquinolones. Clin Infect Dis. 1996;23(Suppl 1):S19–S24
  11. Ravat F, Bourget P, Latarjet J. Pharmacocinétique de la ciprofloxacine chez le patient gravement brûlé infecté. Lettre infectiologue. 1999;14 S:3–6
  12. Drancourt M, Klebsiella. In: Précis de bactériologie clinique, editor. ESKA. p. 1173.
  13. Bornet C, Davin-Régli A, Bollet C, Enterobacter. In: Précis de bactériologie clinique, editor. ESKA. p. 1175.
  14. Carsin H, Bargues L, Stéphanazzi J, Paris A, Aubert P, Le Béver H. Inflammatory reaction and sepsis in severely burned patients. Pathol Biol. 2002;50:93–101
  15. Thomson R, Wright J. General priciples of antimicrobial therapy. Mayo Clin Proc. 1998;73:995–1006
  16. Heggers J, Hawkins H, Edgar P, Villareal C, Herndon D. Treatment of infection in burns. In: Herndon D, editor. Total burn care, 2nd ed. p. 122.
  17. Gales AC, Biedenbach DJ, Winokur P, Hacek DM, Pfaller MA, Jones RN. Carbapenem—resistant Serratia marcessens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: results from the MYSTIC Programme. Diagn Microbiol Infect Dis. 2001;39(2):125–127
  18. Lepper PM, Grusa E, Reich H, Hogel J, Trautmann M. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002;46(9):2920–2925
  19. Fridkin SK. Routine cycling of antimicrobial agents as an infection –control measure. Clin Infect Dis. 2003;36(11):438–444
  20. Kollef M. Appropriate empirical therapy for nosocomial infections: getting it right the first time. Drugs. 2003;63(20):2157–2168
  21. Schentag J, Gilliland K, Paladino J. What have we learned from pharmacokinetic and pharmacodynamic theories?. Clin Infect Dis. 2001;32(Suppl 1):S39–S46
  22. Lesne-Hulin A, Bourget P, Carsin H. Pharmacokinectics of antimicrobial agents in burn patients. Thérapie. 1995;50:575–586
  23. Garraffo R. Intérêt du dosage des antibiotiques en pratique clinique. In: Martin C, Gouin F, editors. Infections et antibiothérapie en réanimation et aux urgences, Arnette. p. 397.

PII: S0305-4179(05)00131-2

doi: 10.1016/j.burns.2005.04.031

Burns
Volume 31, Issue 7 , Pages 866-869 , November 2005

Article Tools